These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35211549)

  • 1. Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer.
    Qin ZQ; Yang SF; Chen Y; Hong CJ; Zhao TW; Yuan GR; Yang L; Gao L; Wang X; Lu LQ
    World J Clin Cases; 2022 Feb; 10(4):1164-1171. PubMed ID: 35211549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.
    Liu X; Guo Z; Su L; Zuo A; Gao M; Ji X; Lu J; Yang S; Jiang Y; Lu D
    Invest New Drugs; 2024 Jun; 42(3):309-317. PubMed ID: 38700579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer.
    Lv W; Pei X; Zhao W; Cong Y; Wei Y; Li T; Zhang H; Lin Z; Saito Y; Kim JJ; Liang Z; Zhong B; Wang Z
    Transl Lung Cancer Res; 2022 Feb; 11(2):201-212. PubMed ID: 35280309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
    Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
    Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of rh-endostatin combined with chemotherapy versus chemotherapy alone for advanced NSCLC: a meta-analysis review].
    Cao D; Ge W; Wang H; Zhang L; Zheng Y; Zhang J
    Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):404-13. PubMed ID: 21569645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer: a phase 2 single-arm multicenter open-label trial.
    Zhao Y; Zhang X; Jin C; Yu X; Zhang M; Cao Y; Li Y; Wang A; Shan X; Zhang J; Wang J; Yin L; Tan X; Liu J
    Ann Palliat Med; 2021 Mar; 10(3):3277-3285. PubMed ID: 33849112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
    Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
    Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.
    Zhang SL; Han CB; Sun L; Huang LT; Ma JT
    Radiat Oncol; 2020 Aug; 15(1):205. PubMed ID: 32831120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
    Li N; Jin ZL; Liu ZJ; Wang J; Li K
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
    Wang B; Xu L; Li Q; Man S; Jin C; Liu L; Zhan S; Ning Y
    BMC Cancer; 2020 Oct; 20(1):1021. PubMed ID: 33087103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
    Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
    Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rh-endostatin Concomitant with Chemotherapy Versus Single Agent Chemotherapy for Treating Soft Tissue and Bone Sarcomas: A Systematic Review and Meta-Analysis.
    Ma Z; Guo L; Cui X; Liu H; Liu L
    J Pharm Pharm Sci; 2018; 21(1):386-397. PubMed ID: 30352660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer].
    Wang J; Li K; Sun T; Zhang MJ; Li WL; Yao Q; Liu W; Ding CM; He ZY; Mao WD; Wang HM; Zhang Y; Zhou XL
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):618-22. PubMed ID: 24314222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
    Ouyang X; Shi M; Jie F; Bai Y; Shen P; Yu Z; Wang X; Huang C; Tao M; Wang Z; Xie C; Wu Q; Shu Y; Han B; Zhang F; Zhang Y; Hu C; Ma X; Liang Y; Wang A; Lu B; Shi Y; Chen J; Zhuang Z; Wang J; Huang J; Wang C; Bai C; Zhou X; Li Q; Chen F; Yu H; Feng J
    Invest New Drugs; 2018 Apr; 36(2):315-322. PubMed ID: 29134432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis.
    Ge W; Cao DD; Wang HM; Jie FF; Zheng YF; Chen Y
    Asian Pac J Cancer Prev; 2011; 12(11):2901-7. PubMed ID: 22393961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis.
    An J; Lv W
    Thorac Cancer; 2018 May; 9(5):606-612. PubMed ID: 29575575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The Comparison of Clinical Effect of Rh-endostar on Retreated Non-Small Cell Lung Cancer and Colorectal Cancer.].
    Yang X; Wang D; Zhong Z; Jin F; Shan J; Wang G; Wang Z; Shen Y
    Zhongguo Fei Ai Za Zhi; 2009 Nov; 12(11):1184-7. PubMed ID: 20723368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.